Key result
Pharmacologic prevention strategies offer options for limiting and preventing cumulative, dose-related anthracycline-induced cardiotoxicity and subsequent heart failure.
Why the study?
Do pharmacologic prevention strategies reduce the risk of anthracycline-induced cardiomyopathy?
Do pharmacologic prevention strategies reduce the risk of anthracycline-induced cardiomyopathy?
This review summarizes the etiology of anthracycline-induced cardiotoxicity and outlines available pharmacologic options for its prevention.
May merit consideration for anthracycline recipients; extends review findings but leaves open need for confirmatory RCTs.
Anthracyclines are highly effective anticancer drugs. However, a major factor limiting their use in humans is a cumulative, dose-related cardiotoxicity which can result in a permanent loss of cardiomyocytes, which ultimately leads to asymptomatic and symptomatic heart failure. Experiences with various approaches to reduce the cardiotoxicity of anthracyclines without jeopardizing their antineoplastic effects have been reported in the oncology literature. This article reviews the etiology and natural history of anthracycline-induced cardiotoxicity and provides options available for limiting and/or preventing cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Maradia et al. (2009) conducted a review in Anthracycline-induced cardiomyopathy. Pharmacologic prevention was evaluated. Pharmacologic prevention strategies offer options for limiting and preventing cumulative, dose-related anthracycline-induced cardiotoxicity and subsequent heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: